Investor Relations
Genomac Holdings operates on a strategic equity and holdings model that creates sustainable value through diversified investments in high-growth sectors of biotechnology, healthcare, and innovation.
Our approach combines direct equity ownership in subsidiaries with active governance, shared service provision, and strategic guidance to maximize returns while driving social impact across Africa.
"Long-term value creation through strategic innovation, operational excellence, and sustainable growth in Africa's biotechnology ecosystem."
Revenue Model
Multiple revenue streams create a diversified and sustainable financial foundation.
Management Fees
Strategic oversight and governance services provided to portfolio companies.
Shared Service Allocation
Finance, HR, legal, IT, and marketing support distributed across subsidiaries.
Dividends & Equity Returns
Returns from subsidiary growth and profitability.
Growth & Expansion
Revenue from licensing, IP, and product commercialization.
Investment Opportunities
Strategic investments driving large-scale impact of Africa's biotechnology ecosystem.
Genomac Labs — Precision Medicine Expansion
Africa faces a critical shortage of genomic diagnostics, with most patients lacking access to genetic testing, early cancer detection, and preventive health screening.
Genomac Labs provides advanced genomic diagnostic services including qPCR-based cancer risk testing and precision health screening with a rollout strategy across major African cities.
- TAM (Global Precision Medicine Market): $98B in 2024, projected to grow to $242B by 2032.
- SAM (Africa Precision Diagnostics Market): $3.2B annually.
- SOM (Nigeria + Ghana + Kenya first-stage rollout): $150M accessible cluster.
- Projected 2–5 year capture: 1–3 percent of SOM (~$1.5M–$4.5M).
Omicsboard (G-iHub) — Digital Research and Innovation Infrastructure
Most African universities, labs, and research institutions lack digital research infrastructure, virtual labs, AI-powered tools, and modern systems for genomics and biotechnology.
Omicsboard is a next-generation digital research and innovation infrastructure platform integrating virtual labs, AI-assisted workflows, scientific training systems, and enterprise biotech capabilities.
- TAM (Global Bioinformatics & Research Software Market): $15B in 2024, projected to reach $38B by 2032.
- SAM (Africa’s digital research education and infrastructure market): $1.1B.
- SOM (Nigeria, Kenya, South Africa academic institutions): $120M accessible cluster.
- Projected 2–5 year capture: 2–5 percent of SOM (~$2.4M–$6M).
G-NATURES — DihemCare Herbal Capsule for Diabetes and Hemorrhoids
Millions of Africans suffer from diabetes and hemorrhoids with limited access to safe, affordable, and scientifically validated natural therapeutic options.
DihemCare is a scientifically developed herbal and nutrigenomics solution targeting diabetes management and hemorrhoid relief, backed by modern research and scalable commercialization.
- TAM (Global Herbal Medicine Market): $210B in 2024, projected to grow to $345B by 2032.
- SAM (Africa’s herbal and nutraceutical market): $18B.
- SOM (Nigeria diabetic and hemorrhoid therapeutic cluster): $1.2B.
- Projected 2–5 year capture: 0.5–2 percent (~$6M–$24M).
Partnership Opportunities
Strategic collaboration opportunities across healthcare, biotechnology, education, and innovation.
Healthcare Institutions
Partnerships with hospitals and clinics for precision medicine and diagnostic services.
Biotech Ventures
Joint ventures in genomics, drug discovery, and therapeutic development.
Academic Institutions
Collaborations with universities for research, training, and capacity building.
Government & NGOs
Public-private partnerships for health initiatives and innovation programs.
Ready to Invest ?
Join us in building Africa's biotechnology future. Contact our investor relations desk to learn more about partnership and investment opportunities.
